Comparable stake leader
Richard E. Uihlein
SEC ownership of GALECTIN THERAPEUTICS INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001133416.
Disclosed value leader
Richard E. Uihlein
Comparable rows
50/50
Latest evidence
31 Jul 2026
- Public ticker
- GALT on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Richard E. Uihlein
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Richard E. Uihlein
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001133416
- Issuer location
- Norcross, GA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of GALECTIN THERAPEUTICS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Richard E. Uihlein
Disclosed value leader
Richard E. Uihlein
Comparable rows
50/50
Latest evidence
31 Jul 2026
13D/G
3/4/5
13F
Lead comparable stake: 49%
13D/G row: Richard E. Uihlein
Showing 1-8 of 50 holder rows.
Quick read
Richard E. Uihlein leads the comparable SEC ownership view at 49%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Richard E. Uihlein's linked filing trail.
Comparable ownership
Top 5
Richard E. Uihlein
49%
10X Fund, L.P.
5.1%
James C. Czirr
0.94%
VANGUARD CAPITAL MANAGEMENT LLC
1.8%
MARSHALL WACE, LLP
1.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Richard E. Uihlein |
13D/G
3/4/5
Director, 10%+ Owner
|
49%
|
$251,498,772
54,673,646 shares
|
$0 | 31 Jul 2026 |
| 10X Fund, L.P. |
3/4/5
10%+ Owner
|
5.1%
|
$37,392,283
5,614,457 shares
|
-$1,581,991 | 02 Dec 2025 |
| James C. Czirr |
3/4/5
10%+ Owner
|
0.94%
|
$1,160,550
1,045,541 shares
|
— | 03 Feb 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
1.8%
|
$5,486,652
1,966,542 shares
|
— | 31 Mar 2026 |
| MARSHALL WACE, LLP |
13F
Company
|
1.1%
|
$3,403,554
1,219,912 shares
|
— | 31 Mar 2026 |
| OSAIC HOLDINGS, INC. |
13F
Company
|
1%
|
$3,132,240
1,122,670 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
0.72%
|
$2,229,871
799,237 shares
|
— | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
0.72%
|
$2,227,631
798,434 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$6,258,045.
Buys
$25,546
Insiders: 2
Sells
$6,283,591
Insiders: 5
Net
-$6,258,045
Shares: -1,150,180
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 7,200
Shares: 1,157,380
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 106,412 | $0 | $521,749 | -$521,749 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 7,200 | 882,145 | $25,546 | $4,819,985 | -$4,794,439 |
| 9-12 | 0 | 168,823 | $0 | $941,856 | -$941,856 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to GALECTIN THERAPEUTICS INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Richard E. Uihlein
Net 12M change
-$6,258,045
Latest report
31 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Richard E. Uihlein | Director, 10%+ Owner | $239,012,140 | Mixed | 31 Jul 2026 | ||
| 10X Fund, L.P. | 10%+ Owner | $37,392,283 | -$1,581,991 | -4.1% | Filing P/S | 02 Dec 2025 |
| Joel Lewis | President and CEO, Director | $3,213,845 | -$709,585 | -18% | Mixed | 16 Jan 2026 |
| James C. Czirr | 10%+ Owner | $1,160,550 | Mixed | 03 Feb 2025 | ||
| Kevin D. Freeman | Director | $760,936 | +$19,514 | +2.6% | Mixed | 16 Jan 2026 |
| Kary Eldred | Director | $190,925 | +$6,032 | +3.3% | Mixed | 06 Feb 2026 |
| Jack W. Callicutt | Chief Financial Officer | $143,301 | -$1,000,450 | -87% | Mixed | 16 Jan 2026 |
| Pol F. Boudes | Chief Medical Officer | $71,432 | Mixed | 24 Jan 2024 | ||
| Khurram Jamil | Chief Medical Officer | $69,600 | -$1,435,731 | -95% | Mixed | 14 Jul 2026 |
| Harold H. Shlevin | Director | $32,760 | -$1,555,834 | -98% | Filing P/S | 26 Jun 2026 |
| Henry Brem | Director | $0 | Mixed | 12 Mar 2026 | ||
| Gilbert F. Amelio | Director | Mixed | 16 Jan 2026 | |||
| Power Benjamin Carson Sr. | Director | Mixed | 16 Jan 2026 | |||
| Marc Rubin | Director | Mixed | 23 Jan 2025 | |||
| Elissa J. Schwartz | Director | Mixed | 16 Jan 2026 | |||
| Gilbert S. Omenn | Director | Mixed | 16 Jan 2026 | |||
| Richard A. Zordani Jr. | Director | Mixed | 16 Jan 2026 |
Recent insider transactions for GALECTIN THERAPEUTICS INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Richard E. Uihlein | GALT | Common Stock | Options Exercise | 332.5% | 34,376,167 | 44,713,843 | 31 Jul 2026 | Richard E. Uihlein Stock Trust | ||
| Richard E. Uihlein | GALT | Line of Credit Convertible Notes | Options Exercise | 0 | 0 | 31 Jul 2026 | Richard E. Uihlein Stock Trust | |||
| Khurram Jamil | GALT | Common Stock | Sale | -100% | $83,284 | $5.13 | -16,250 | 0 | 14 Jul 2026 | Direct |
| Khurram Jamil | GALT | Common Stock | Options Exercise | 16,250 | 16,250 | 14 Jul 2026 | Direct | |||
| Khurram Jamil | GALT | Stock option (right to buy) | Options Exercise | -25% | -16,250 | 48,750 | 14 Jul 2026 | Direct | ||
| Harold H. Shlevin | GALT | Common Stock | Sale | -77.4% | $112,231 | $5.04 | -22,268 | 6,500 | 29 Jun 2026 | Direct |
| Harold H. Shlevin | GALT | Common Stock | Options Exercise | 342.6% | 22,268 | 28,768 | 29 Jun 2026 | Direct | ||
| Harold H. Shlevin | GALT | Stock Option (right to buy) | Options Exercise | -42.6% | -22,268 | 30,000 | 29 Jun 2026 | Direct | ||
| Khurram Jamil | GALT | Common Stock | Sale | -100% | $239,234 | $5.04 | -47,467 | 0 | 29 Jun 2026 | Direct |
| Khurram Jamil | GALT | Common Stock | Options Exercise | 47,467 | 47,467 | 29 Jun 2026 | Direct | |||
| Khurram Jamil | GALT | Stock Option (right to buy) | Options Exercise | -100% | -47,467 | 0 | 29 Jun 2026 | Direct | ||
| Harold H. Shlevin | GALT | Common Stock | Sale | -54.3% | $38,660 | $5.00 | -7,732 | 6,500 | 26 Jun 2026 | Direct |
| Harold H. Shlevin | GALT | Common Stock | Options Exercise | 119% | 7,732 | 14,232 | 26 Jun 2026 | Direct | ||
| Harold H. Shlevin | GALT | Stock Option (right to buy) | Options Exercise | -12.9% | -7,732 | 52,268 | 26 Jun 2026 | Direct | ||
| Khurram Jamil | GALT | Common Stock | Sale | -100% | $22,850 | $5.00 | -4,570 | 0 | 26 Jun 2026 | Direct |
| Khurram Jamil | GALT | Common Stock | Options Exercise | 4,570 | 2,533 | 26 Jun 2026 | Direct | |||
| Khurram Jamil | GALT | Stock Option (right to buy) | Options Exercise | -8.78% | -4,570 | 47,467 | 26 Jun 2026 | Direct | ||
| Khurram Jamil | GALT | Common Stock | Sale | -100% | $23,729 | $3.14 | -7,557 | 0 | 23 Jun 2026 | Direct |
| Khurram Jamil | GALT | Common Stock | Options Exercise | 7,557 | 7,557 | 23 Jun 2026 | Direct | |||
| Khurram Jamil | GALT | Stock option (right to buy) | Options Exercise | -18.9% | -7,557 | 32,500 | 23 Jun 2026 | Direct | ||
| Khurram Jamil | GALT | Common Stock | Sale | -100% | $1,761 | $3.10 | -568 | 0 | 26 May 2026 | Direct |
| Khurram Jamil | GALT | Common Stock | Options Exercise | 568 | 568 | 26 May 2026 | Direct | |||
| Khurram Jamil | GALT | Stock option (right to buy) | Options Exercise | -1.4% | -568 | 40,057 | 26 May 2026 | Direct | ||
| Henry Brem | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 12 Mar 2026 | Direct | |||
| Kary Eldred | GALT | Common Stock | Purchase | 0.46% | $810 | $2.70 | 300 | 65,682 | 06 Feb 2026 | Direct |
| Joel Lewis | GALT | Stock option (right to buy) | Award | 91,000 | 91,000 | 16 Jan 2026 | Direct | |||
| Benjamin Carson Sr. | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 16 Jan 2026 | Direct | |||
| Richard A. Zordani Jr. | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 16 Jan 2026 | Direct | |||
| Khurram Jamil | GALT | Restricted Stock Unit | Award | 100,000 | 100,000 | 16 Jan 2026 | Direct | |||
| Khurram Jamil | GALT | Stock option (right to buy) | Award | 65,000 | 65,000 | 16 Jan 2026 | Direct | |||
| Kevin D. Freeman | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 16 Jan 2026 | Direct | |||
| Kary Eldred | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 16 Jan 2026 | Direct | |||
| Jack W. Callicutt | GALT | Restricted Stock Unit | Award | 100,000 | 100,000 | 16 Jan 2026 | Direct | |||
| Jack W. Callicutt | GALT | Stock option (right to buy) | Award | 65,000 | 65,000 | 16 Jan 2026 | Direct | |||
| Harold H. Shlevin | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 16 Jan 2026 | Direct | |||
| Gilbert S. Omenn | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 16 Jan 2026 | Direct | |||
| Gilbert F. Amelio | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 16 Jan 2026 | Direct | |||
| Elissa J. Schwartz | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 16 Jan 2026 | Direct | |||
| Richard E. Uihlein | GALT | Common Stock | Award | 0.13% | 13,158 | 10,332,676 | 16 Jan 2026 | Direct | ||
| Richard E. Uihlein | GALT | Stock option (right to buy) | Award | 60,000 | 60,000 | 16 Jan 2026 | Direct | |||
| Joel Lewis | GALT | Common Stock | Sale | -4.33% | $134,853 | $3.58 | -37,698 | 832,592 | 06 Jan 2026 | Direct |
| Jack W. Callicutt | GALT | Common Stock | Sale | -72.8% | $74,695 | $3.67 | -20,354 | 7,614 | 06 Jan 2026 | Direct |
| Khurram Jamil | GALT | Common Stock | Sale | -100% | $78,205 | $3.65 | -21,446 | 0 | 06 Jan 2026 | Direct |
| Joel Lewis | GALT | Common Stock | -6.77% | -56,332 | 776,260 | 05 Jan 2026 | Direct | |||
| Joel Lewis | GALT | Common Stock | Sale | -3.09% | $108,342 | $3.91 | -27,731 | 870,290 | 05 Jan 2026 | Direct |
| Jack W. Callicutt | GALT | Common Stock | Sale | -47.9% | $100,298 | $3.90 | -25,732 | 27,968 | 05 Jan 2026 | Direct |
| Khurram Jamil | GALT | Common stock | Sale | -54.3% | $99,408 | $3.90 | -25,499 | 21,446 | 05 Jan 2026 | Direct |
| Joel Lewis | GALT | Common Stock | Sale | -2.03% | $77,939 | $4.20 | -18,571 | 898,021 | 02 Jan 2026 | Direct |
| Joel Lewis | GALT | Common Stock | Options Exercise | 10.1% | 84,000 | 916,592 | 02 Jan 2026 | Direct | ||
| Joel Lewis | GALT | Restricted Stock Unit | Options Exercise | -100% | -84,000 | 0 | 02 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.